David Raben's most recent trade in Bicara Therapeutics Inc. was a trade of 5,500 Common Stock done at an average price of $3.8 . Disclosure was reported to the exchange on April 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 27 Apr 2026 | 5,500 | 60,786 | - | 3.8 | 20,844 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 27 Apr 2026 | 5,500 | 41,913 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.88 per share. | 27 Apr 2026 | 5,500 | 55,286 | - | 22.9 | 125,830 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 25 Mar 2026 | 5,500 | 47,413 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 25 Mar 2026 | 5,500 | 60,786 | - | 3.8 | 20,844 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.95 per share. | 25 Mar 2026 | 5,500 | 55,286 | - | 19.0 | 104,229 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 16,300 | 71,586 | - | 3.8 | 61,774 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.52 per share. | 03 Mar 2026 | 16,300 | 55,286 | - | 18.5 | 301,920 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 03 Mar 2026 | 16,300 | 52,913 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 200 | 55,486 | - | 3.8 | 758 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 03 Mar 2026 | 200 | 55,286 | - | 18.5 | 3,690 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 03 Mar 2026 | 200 | 69,213 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 02 Feb 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 26 Dec 2025 | 19,789 | 98,987 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 26 Dec 2025 | 19,789 | 55,286 | - | 3.8 | 74,996 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 5,500 | 40,997 | - | 3.8 | 20,844 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 24 Nov 2025 | 5,500 | 35,497 | - | 18.5 | 101,475 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 24 Nov 2025 | 5,500 | 123,370 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 24 Nov 2025 | 4,594 | 35,497 | - | 18.8 | 86,562 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 4,594 | 40,091 | - | 3.8 | 17,410 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 24 Nov 2025 | 4,594 | 118,776 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 906 | 36,403 | - | 3.8 | 3,434 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 24 Nov 2025 | 906 | 69,413 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 24 Nov 2025 | 906 | 35,497 | - | 18.8 | 17,071 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | 09 Oct 2025 | 22,000 | 128,870 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 09 Oct 2025 | 22,000 | 35,497 | - | 18.5 | 405,900 | Common Stock |
| Bicara Therapeutics Inc | Dr. David Raben, M.D. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 09 Oct 2025 | 22,000 | 57,497 | - | 3.8 | 83,376 | Common Stock |